James Longe, MD
Sports Medicine · Salt Lake City, UTNPI 1093730129
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 147 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AbbVie at 25.6% of the total. Reporting peaked in 2023 at $691 and has fallen 97.0% since, to $21 in 2025.
Across 147 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$668
- Lilly USA, LLC$267
- Abbott$208
- GSK$169
- Boehringer Ingelheim$157
- Dynavax Technologies Corporation$98
- plus $1K from 28 others
What the payments were for
- Food & beverage$2,611100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 28 | $668 |
| Lilly USA, LLC | 17 | $267 |
| Abbott | 10 | $208 |
| GSK | 10 | $169 |
| Boehringer Ingelheim | 8 | $157 |
| Dynavax Technologies Corporation | 5 | $98 |
| Amgen(2 entities) | 6 | $96 |
| AstraZeneca | 7 | $85 |
| Bayer | 5 | $81 |
| Novartis | 5 | $78 |
| Pfizer | 6 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $56 |
| Johnson & Johnson | 3 | $50 |
| Gilead | 3 | $47 |
| Quidel Corporation | 1 | $41 |
| Corium, LLC | 2 | $40 |
| Seqirus USA Inc | 3 | $38 |
| Biohaven Pharmaceuticals, Inc. | 2 | $36 |
| Corcept Therapeutics | 2 | $32 |
| Genentech USA, Inc. | 2 | $31 |
| Boston Scientific | 2 | $30 |
| Lucid Diagnostics Inc. | 2 | $29 |
| Novo Nordisk | 2 | $27 |
| Cranial Technologies, Inc | 2 | $26 |
| Merck | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Hologic Sales And Service, LLC | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
| Axonics, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$2,611 in reported general payments places this provider in the 70th percentile of 83 sports medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 15 | $21,581 |
| MyrbetriqMirabegron | 11 | $5,794 |
| Levothyroxine Sodium | 279 | $3,521 |
| Atorvastatin Calcium | 275 | $2,785 |
| Omeprazole | 144 | $2,450 |
| Estradiol | 34 | $1,700 |
| Quetiapine Fumarate | 59 | $1,540 |
| Gabapentin | 66 | $1,513 |
| Bupropion XlBupropion Hcl | 37 | $1,436 |
| Zolpidem Tartrate | 136 | $1,278 |
| Tamsulosin Hcl | 99 | $1,268 |
| Lisinopril | 143 | $1,081 |
| Trazodone Hcl | 96 | $1,050 |
| Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide | 40 | $1,049 |
| Rosuvastatin Calcium | 70 | $1,048 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $267 | $21,58115 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $5,79411 claims |
| AbbVieSynthroid | $668 | $71418 claims |
| PfizerLevoxyl | $73 | $45716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 83 sports medicine providers in Utah.
Other sports medicine in Salt Lake City
- Andrew CooperSalt Lake City$22K
- Mark SchollSalt Lake City$18K
- Matthew CraigSalt Lake City$14K
- William JohnsSalt Lake City$9K
- Charles HollidaySalt Lake City$8K
- Wesley LewisSalt Lake City$5K
- Jared DunnSalt Lake City$2K
- David PetronSalt Lake City$273
- Mark SederbergSalt Lake City$242
- Brian HillSalt Lake City$216
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.